Search

Your search keyword '"Pezzutto, Antonio"' showing total 408 results
Start Over Author "Pezzutto, Antonio"
408 results on '"Pezzutto, Antonio"'

3. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study

Author

Rambaldi, Alessandro, Iurlo, Alessandra, Vannucchi, Alessandro M., Noble, Richard, von Bubnoff, Nikolas, Guarini, Attilio, Martino, Bruno, Pezzutto, Antonio, Carli, Giuseppe, De Muro, Marianna, Luciani, Stefania, McMullin, Mary Frances, Cambier, Nathalie, Marolleau, Jean-Pierre, Mesa, Ruben A., Tibes, Raoul, Pancrazzi, Alessandro, Gesullo, Francesca, Bettica, Paolo, Manzoni, Sara, and Di Tollo, Silvia

Published
2020
Full Text
View/download PDF

9. Efficient non-viral T cell engineering for TCR gene therapy by Sleeping Beauty minicircles

Author

Uckert, Wolfgang, Matuschewski, Kai, Pezzutto, Antonio, Clauß, Julian, Uckert, Wolfgang, Matuschewski, Kai, Pezzutto, Antonio, and Clauß, Julian

Abstract

Sleeping Beauty (SB) Transposon-basierte Vektoren werden als Alternative zu viralen Vektoren für T-Zell-Gentherapie erforscht und ermöglichen eine schnelle und kostengünstige Genmanipulation von T-Zellen. Die Verwendung von Transposon-Vektoren erfordert jedoch die DNA-Elektroporation von T-Zellen, die sich schädlich auf T-Zellen auswirkt. DNA-elektroporierte T-Zellen weisen eine verringerte Lebensfähigkeit und eine verzögerte Aktivierung nach Stimulation des T-Zell-Rezeptors (TCR) auf. Um die Nachteile der Transposon-basierten T-Zell-Genmanipulation zu überwinden, haben wir neuartige SB-Vektoren entwickelt. Durch die Kombination von SB Transposon-basierten Minicircle-Vektoren mit SB100X Transposase-mRNA konnten T-Zellen effizient genmodifiziert werden. Unser Ansatz reduzierte die T-Zell-Mortalität und steigerte gleichzeitig die Transfektionseffizienz. Mit diesen neuartigen Vektoren wurde die stabile Expression verschiedener TCRs und CARs in über 50% der eingesetzten T-Zellen erreicht. Gentechnisch manipulierte T-Zellen konnten Antigen-spezifisch stimuliert werden und zeigten effiziente Zytokin-Sekretion und Tumorzell-Lyse. Weiterhin haben wir miRNAs entwickelt, die die Expression der endogenen TCR-Ketten unterdrücken. Der Einbau dieser miRNAs in die TCR-Expressionskassette erhöhte die Oberflächenexpression des therapeutischen TCRs, verringerte die Fehlpaarung mit endogenen TCR-Ketten und erhöhte die T-Zell-Funktionalität. Ein direkter Vergleich von SB- und Virus-modifizierten T-Zellen zeigte sowohl in vitro als auch in vivo eine vergleichbare Wirksamkeit der modifizierten T-Zellen hinsichtlich Zytokin-Sekretion, Tumorzell-Lyse und Tumorkontrolle. In dieser Arbeit konnte gezeigt werden, dass SB Minicircle-Vektoren die Herstellung von genetisch modifizierten T-Zellen ermöglichen und diese Tumor-spezifische Wirksamkeit aufweisen. Dieser Ansatz könnte die Herstellung therapeutischer T-Zellen für die personalisierte T-Zell-Gentherapie vereinfachen und beschleunigen., Sleeping Beauty (SB) transposon-based vectors have entered clinical trials as an alternative to viral vectors for T cell gene therapy, offering time- and cost-efficient engineering of therapeutic T cells. However, transposon vectors require DNA electroporation into T cells, which we found to cause adverse effects. T cell viability was decreased, and DNA-transfected T cells showed delayed activation upon T cell receptor (TCR) stimulation regarding blast formation and proliferation. To overcome the limitations of transposon-based T cell engineering, we investigated the effect of DNA electroporation on T cells and developed novel SB vectors. T cells could efficiently be engineered with Sleeping Beauty vectors by combining SB transposon minicircles and SB100X transposase mRNA. Our approach reduced T cell mortality and substantially enhanced transfection efficiency. We achieved stable expression of several TCRs and CARs in more than 50% of the transfected T cells compared to 15% when conventional plasmids were used. T cells engineered to express a tumor-specific TCR mediated effective tumor cell lysis and cytokine secretion upon antigen-specific stimulation. Furthermore, we developed miRNAs to silence the expression of the endogenous TCR chains. Incorporation of these miRNAs into the TCR expression cassette increased surface expression of the therapeutic TCR, diminished mispairing with endogenous TCR chains, and enhanced T cell functionality. Importantly, a direct comparison of SB minicircle- and RV-engineered T cells in vitro as well as in vivo demonstrated equal T cell efficacy with regards to cytokine release, tumor cell lysis and tumor control. We demonstrated that SB minicircles enable the generation of gene-modified T cells with tumor-specific reactivity. Our approach facilitates the manufacturing of therapeutic T cells with superior biosafety and accelerates the generation of patient-specific T cell products for personalized T cell gene therapy.

Published
2023

10. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Author

Saußele, Susanne, Krauß, Marie-Paloma, Hehlmann, Rüdiger, Lauseker, Michael, Proetel, Ulrike, Kalmanti, Lida, Hanfstein, Benjamin, Fabarius, Alice, Kraemer, Doris, Berdel, Wolfgang E., Bentz, Martin, Staib, Peter, de Wit, Maike, Wernli, Martin, Zettl, Florian, Hebart, Holger F., Hahn, Markus, Heymanns, Jochen, Schmidt-Wolf, Ingo, Schmitz, Norbert, Eckart, Michael J., Gassmann, Winfried, Bartholomäus, Andrea, Pezzutto, Antonio, Leibundgut, Elisabeth Oppliger, Heim, Dominik, Krause, Stefan W., Burchert, Andreas, Hofmann, Wolf-Karsten, Hasford, Joerg, Hochhaus, Andreas, Pfirrmann, Markus, and Müller, Martin C.

Published
2015
Full Text
View/download PDF

11. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Author

Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)

Subjects
0301 basic medicine, Male, cd52 expression, Cancer Research, epstein-barr-virus, medicine.medical_treatment, CHOP, Gastroenterology, PROPHYLAXIS, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Significant risk, Alemtuzumab, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Hematology, lymphoproliferative disorders, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, 3. Good health, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Toxicity, PHASE-II, Female, medicine.drug, medicine.medical_specialty, prognostic-factors, Medication Adherence, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, non-hodgkin-lymphoma, Cyclophosphamide, Aged, Chemotherapy, therapy, business.industry, Lymphoma, T-Cell, Peripheral, DETUDE-DES-LYMPHOMES, medicine.disease, Survival Analysis, Peripheral T-cell lymphoma, 030104 developmental biology, Doxorubicin, Prednisone, business
Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021

17. High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination

Author

Pohla, Heike, Buchner, Alexander, Stadlbauer, Birgit, Frankenberger, Bernhard, Stevanovic, Stefan, Walter, Steffen, Frank, Ronald, Schwachula, Tim, Olek, Sven, Kopp, Joachim, Willimsky, Gerald, Stief, Christian G, Hofstetter, Alfons, Pezzutto, Antonio, Blankenstein, Thomas, Oberneder, Ralph, and Schendel, Dolores J

Published
2012
Full Text
View/download PDF

19. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Author

UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, and ACT-2 study investigators

Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%-39%], 28% [15%-40%], and 37% ([23%-50%] for A-CHOP, and 24% [12%-35%], 29% [17%-41%], and 56% [44%-69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HR: 0.7 ([95% CI: 0.5-1.1]; p = 0.094), HR: 0.8 ([95% CI: 0.5-1.2]; p = 0.271), HR: 1.4 ([95% CI: 0.9-2.4]; p = 0.154). The IPI score was validated, and male sex (HR 2.5) and bulky disease (HR 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021

22. Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care

Author

Albrecht, Annemarie, primary, Porthun, Jan, additional, Eucker, Jan, additional, Coats, Andrew, additional, von Haehling, Stephan, additional, Pezzutto, Antonio, additional, Karakas, Mahir, additional, Riess, Hanno, additional, Keller, Ulrich, additional, Landmesser, Ulf, additional, Haverkamp, Wilhelm, additional, Anker, Stefan, additional, and Anker, Markus, additional

Published
2021
Full Text
View/download PDF

23. Long‐term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges

Author

Herda, Stefanie, primary, Heimann, Andreas, additional, Obermayer, Benedikt, additional, Ciraolo, Elisa, additional, Althoff, Stefanie, additional, Ruß, Josefine, additional, Grunert, Corinna, additional, Busse, Antonia, additional, Bullinger, Lars, additional, Pezzutto, Antonio, additional, Blankenstein, Thomas, additional, Beule, Dieter, additional, and Na, Il‐Kang, additional

Published
2021
Full Text
View/download PDF

40. Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease

Author

Rieger, Kathrin, Günther, Ute, Erben, Ulrike, Kühl, Anja, Loddenkemper, Christoph, Pezzutto, Antonio, Siegmund, Britta, Bojarski, Christian, and Maurer, Martin

Subjects
immune system diseases, hemic and lymphatic diseases, 610 Medicine & health
Abstract

Graft-versus-host disease (GvHD) is a major complication of allogeneic stem cell transplantation. High-resolution in vivo histology of the intestine by confocal endomicroscopy (CEM) detects acute GvHD (aGvHD) with high sensitivity. This pilot study aims to evaluate the diagnostic value of CEM for intestinal chronic GvHD (cGvHD). The study included 20 patients with gastrointestinal symptoms and confirmed cGvHD in other organs as well as 20 patients with clinically suspected acute GvHD for control. Confocal endomicroscopy was performed as gastroscopy followed by sigmoidoscopy after intravenous injection of fluorescein (10%) and topical application of acriflavine (0.05%). Histopathology from H&E-stained biopsy samples throughout the intestinal tract complemented the survey. All histological features of intestinal cGvHD were predominantly mild to moderate. Stroma fibrosis detected by standard histology (16/20 patients) was not seen by CEM. Apoptosis assessed by histology in 12/20 patients was concordant with CEM (8/12 patients). Confocal endomicroscopy revealed esophageal manifestation of cGvHD in 3 patients. For each biopsy site, CEM correlated with intestinal histology (r = 0.64). Classical histology from intestinal biopsy samples taken under CEM monitoring confirmed the final diagnosis of cGvHD. The sensitivity of CEM with 40% in cGvHD was significantly lower compared to 70% in patients with aGvHD. Confocal endomicroscopy detected acute features of cGvHD and contributed to the diagnosis of esophageal cGvHD but failed to display stroma fibrosis in vivo. Although CEM represents a useful noninvasive tool in routine diagnostic of intestinal aGvHD, the method is not sufficient to fully establish the diagnosis of cGvHD within the intestinal tract. Confocal endomicroscopy allowed acquisition of targeted biopsies in patients suspected of having cGvHD.

Published
2018
Full Text
View/download PDF

41. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Author

Horwitz, Steven, primary, O'Connor, Owen A, additional, Pro, Barbara, additional, Illidge, Tim, additional, Fanale, Michelle, additional, Advani, Ranjana, additional, Bartlett, Nancy L, additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana, additional, Lennard, Anne, additional, Belada, David, additional, Illés, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei, additional, Hüttmann, Andreas, additional, Savage, Kerry J, additional, Yuen, Sam, additional, Iyer, Swaminathan, additional, Zinzani, Pier Luigi, additional, Hua, Zhaowei, additional, Little, Meredith, additional, Rao, Shangbang, additional, Woolery, Joseph, additional, Manley, Thomas, additional, Trümper, Lorenz, additional, Aboulafia, David, additional, Alpdogan, Onder, additional, Ando, Kiyoshi, additional, Arcaini, Luca, additional, Baldini, Luca, additional, Bellam, Naresh, additional, Bartlett, Nancy, additional, Yehuda, Dina Ben, additional, Benedetti, Fabio, additional, Borchman, Peter, additional, Bordessoule, Dominique, additional, Brice, Pauline, additional, Briones, Javier, additional, Caballero, Dolores, additional, Carella, Angelo Michele, additional, Chang, Hung, additional, Cheong, June Weon, additional, Cho, Seok-Goo, additional, Choi, Ilseung, additional, Choquet, Sylvain, additional, Colita, Andrei, additional, Congui, Angela Giovanna, additional, D'amore, Francesco, additional, Dang, Nam, additional, Davison, Kelly, additional, de Guibert, Sophie, additional, Brown, Peter de Nully, additional, Delwail, Vincent, additional, Demeter, Judit, additional, di Raimondo, Francesco, additional, Do, Young Rok, additional, Domingo, Eva, additional, Douvas, Michael, additional, Dreyling, Martin, additional, Ernst, Thomas, additional, Fay, Keith, additional, Ferrero, Silvia Fernandez, additional, Flinn, Ian Winchester, additional, Forero-Torres, Andres, additional, Fox, Christopher, additional, Friedberg, Jonathan, additional, Fukuhara, Noriko, additional, Garcia-Marco, Jose, additional, Cruz, Jorge Gayoso, additional, Codina, Jose Gomez, additional, Gressin, Remy, additional, Grigg, Andrew, additional, Gurion, Ronit, additional, Haioun, Corinne, additional, Hajek, Roman, additional, Hanel, Mathias, additional, Hatake, Kiyohiko, additional, Hensen, Robert, additional, Horowitz, Netanel, additional, Horwitz, Steven, additional, Huttmann, Andreas, additional, Illes, Arpad, additional, Ishizawa, Kenichi, additional, Islas-Ohlmayer, Miguel, additional, Jacobsen, Eric, additional, Janakiram, Murali, additional, Jurczak, Wojciech, additional, Kaminski, Mark, additional, Kato, Koji, additional, Kirgner, Ilya, additional, Kuo, Ching-Yuan, additional, Lazaroiu, Mihaela Cornelia, additional, Du, Katell Le, additional, Lee, Jong-Seok, additional, LeGouill, Steven, additional, LaRosee, Paul, additional, Levi, Itai, additional, Link, Brian, additional, Maisonneuve, Herve, additional, Maruyama, Dai, additional, Mayer, Jiri, additional, McCarty, John, additional, McKay, Pam, additional, Minami, Yosuke, additional, Mocikova, Heidi, additional, Morra, Enrica, additional, Munoz, Javier, additional, Nagai, Hirokazu, additional, O'Connor, Owen, additional, Opat, Stephen, additional, Pettengell, Ruth, additional, Pezzutto, Antonio, additional, Pfreundschuh, Michael, additional, Pluta, Andrzej, additional, Porcu, PierLuigi, additional, Quach, Hang, additional, Rambaldi, Alessandro, additional, Renwick, William, additional, Reyes, Ruben, additional, Izquierdo, Antonia Rodriguez, additional, Ruan, Jia, additional, Rusconi, Chiara, additional, Salles, Gilles, additional, Santoro, Armando, additional, Sarriera, Jose, additional, Savage, Kerry, additional, Shibayama, Hirohiko, additional, Suh, Cheolwon, additional, Sureda, Anna, additional, Tanimoto, Mitsune, additional, Taniwaki, Masafumi, additional, Tilly, Herve, additional, Trneny, Marek, additional, Trumper, Lorenz, additional, Tsukamoto, Norifumi, additional, Vitolo, Umberto, additional, Walewski, Jan, additional, Weidmann, Eckhart, additional, Wilhelm, Martin, additional, Witzens-Harig, Mathias, additional, Yacoub, Abdulraheem, additional, Yamamoto, Kazuhito, additional, Yoon, Sung-Soo, additional, Yun, Hwan Jung, additional, and Zain, Jasmine, additional

Published
2019
Full Text
View/download PDF

42. Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report

Author

Sturm Isrid, Oertel Joachim, Oertel Stephan, Westermann Jörg, and Pezzutto Antonio

Subjects
Medicine
Abstract

Abstract Introduction Treatment of chronic lymphocytic leukemia of the B-cell-lineage is strongly based upon clinical staging because of the heterogeneous clinical course of this disease. Case presentation We describe a 62-year-old patient with newly diagnosed chronic lymphocytic leukemia of the B-cell-lineage who did not respond to several chemotherapy regimens including chlorambucil, fludarabine and cyclophosphamide, developing a marked neutropenia and thrombocytopenia with life-threatening infections. Further chemotherapy appeared not feasible because of bone marrow toxicity. The patient was treated with 600 mg/m2 rituximab weekly followed by eight courses of biweekly therapy and then by long-term maintenance therapy, achieving almost complete remission of the symptoms and disease control. Conclusion After resistance to standard chemotherapy with chlorambucil and fludarabine, a patient with chronic lymphocytic leukemia of the B-cell-lineage was successfully treated with rituximab.

Published
2008
Full Text
View/download PDF

44. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Author

d'Amore, Francesco, primary, Leppä, Sirpa, additional, Silva, Maria Gomes da, additional, Relander, Thomas, additional, Lauritzsen, Grete Fossum, additional, Brown, Peter De Nully, additional, Pezzutto, Antonio, additional, Doorduijn, Jeanette K., additional, Weidmann, Eckhart, additional, van Gelder, Michel, additional, Hoof, Achiel Van, additional, Christiansen, Ilse, additional, Fagerli, Unn Merete, additional, Hagberg, Hans, additional, Lugtenburg, P.J., additional, Walewski, Jan, additional, Wu, Ka Lung, additional, Demuynck, Hilde Maria, additional, Fijnheer, Rob, additional, Christensen, Jacob H., additional, Jankovská, Milada, additional, Josefsson, Pär L., additional, Kluin-Nelemans, Hanneke, additional, Mariz, Jose Mario, additional, Merup, Mats A., additional, Noesslinger, Thomas, additional, Van Den Neste, Eric, additional, Zijlstra, Josée M, additional, Hopfinger, Georg, additional, Prochazka, VIT, additional, Jantunen, Esa, additional, Boudova, Ludmila, additional, Cabecadas, Jose, additional, Chott, Andreas, additional, Delabie, Jan M.A., additional, de Leval, Laurence, additional, Diepstra, Arjan, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Noergaard, Peter, additional, Rosenwald, Andreas, additional, Rymkiewicz, Grzegorz, additional, Sundström, Christer, additional, Truemper, Lorenz, additional, Wulf, Gerald, additional, Chong, Lauren, additional, Bouska, Alyssa, additional, Smith, Lynette, additional, Gisselbrecht, Christian, additional, Ziepert, Marita, additional, Loeffler, Markus, additional, Liestol, Knut, additional, Steidl, Christian, additional, Gascoyne, Randy D., additional, Scott, David W., additional, Altmann, Bettina, additional, Iqbal, Javeed, additional, Chan, Wing C, additional, and Toldbod, Helle, additional

Published
2018
Full Text
View/download PDF

45. Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Author

Hehlmann, Rüdiger, primary, Lauseker, Michael, additional, Saussele, Susanne, additional, Pfirrmann, Markus, additional, Krause, Stefan W., additional, Kolb, Hans-Jochem, additional, Neubauer, Andreas, additional, Hossfeld, Dieter K., additional, Nerl, Christoph, additional, Gratwohl, Alois, additional, Baerlocher, Gabriela M., additional, Heim, Dominik, additional, Bruemmendorf, Tim Henrik, additional, Fabarius, Alice, additional, Haferlach, Claudia, additional, Schlegelberger, Brigitte, additional, Müller, Martin C., additional, Jeromin, Sabine, additional, Proetel, Ulrike, additional, Kohlbrenner, Katharina, additional, Voskanyan, Astghik, additional, Rinaldetti, Sébastien, additional, Seifarth, Wolfgang, additional, Spiess, Birgit, additional, Balleisen, Leopold, additional, Goebeler, Maria E, additional, Hänel, Mathias, additional, Ho, Anthony D., additional, Dengler, J, additional, Falge, C, additional, Kanz, Lothar, additional, Köhne, Claus-Henning, additional, Burchert, Andreas, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Köhne, C, additional, Lindemann, Hans-Walter, additional, Waller, C, additional, Pfreundschuh, Michael, additional, Spiekermann, Karsten, additional, Berdel, Wolfgang E, additional, Müller, L, additional, Edinger, Matthias, additional, Mayer, Jiri, additional, Beelen, Dietrich W, additional, Bentz, Martin, additional, Link, Hartmut, additional, Hertenstein, Bernd, additional, Fuchs, R, additional, Wernli, Martin, additional, Schlegel, F, additional, Schlag, Rudolph, additional, de Wit, M, additional, Trümper, Lorenz, additional, Hebarth, H, additional, Hahn, M, additional, Thomalla, Jörg, additional, Scheid, Christof, additional, Schafhausen, Philippe, additional, Verbeek, Walter, additional, Eckart, Michael J., additional, Gassmann, Winfried, additional, Pezzutto, Antonio, additional, Schenk, Michael, additional, Brossart, Peter, additional, Geer, Thomas, additional, Bildat, Stephan, additional, Schäfer, E, additional, Hochhaus, Andreas, additional, and Hasford, Joerg, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results